Table 1.
Patients’ Demographics (N=33)
| Demographic Characteristics | |
|---|---|
| Age | |
| Age (years; mean ± sd) (95% CI) | 40.91±13.61 (36.08, 45.74) |
| Gender, N (%) | |
| Male | 24 (72.73) |
| Female | 9 (27.27) |
| Surgeries, median (range) | 2 (1, 5) |
| ECOG performance status at enrollment, N (%) | |
| 0 | 14 (42.42) |
| 1 | 19 (57.58) |
| Subtypes of chondrosarcoma, N (%) | |
| Common type, grades 2–3 | 20 (60.61) |
| Dedifferentiated type | 5 (15.15) |
| Mesenchymal type | 4 (12.12) |
| Extraskeletal myxoid chondrosarcoma | 3 (9.09) |
| Clear-cell type | 1 (3.03) |
| Median target lesion size at baseline (95% CI), mm | 64.30 (57.59, 91.48) |
| <60mm, N (%) | 16 (48.48) |
| ≥60mm, N (%) | 17 (51.51) |
| Locations of lesions before using apatinib, N (%) | |
| Pulmonary lesions only | 9 (27.27) |
| Musculoskeletal lesions only | 4 (12.12) |
| Both at pulmonary lesions and musculoskeletal lesions as well as visceral infiltration | 20 (60.61) |
| Primary tumor location, N (%) | |
| Extremities | 10 (30.30) |
| Axial skeleton | 19 (57.58) |
| Multiple lesions (malignancy transformation from endochondromatosis) | 1 (3.03) |
| Maxillofacial region | 2 (6.06) |
| Ribs | 1 (3.03) |
| Time interval from diagnosis to apatinib treatment, N (%) | |
| (months; mean ± sd) (95% CI) | 19.92±19.87 (12.87, 26.96) |
| ≤24 months | 16 (48.48) |
| >24 months | 17 (51.52) |
| Previous antineoplastic treatments, N (%) | |
| Treatment naïve | 18 (54.55) |
| ≥1 chemotherapy | 13 (39.39) |
| Target therapy | 2 (6.06) |
| Prior radiation | |
| Yes | 1 (3.03) |
| No | 32 (97.00) |
| Patients’ reason for stopping apatinib, N (%) | 28 (100.00) |
| Disease progression | 17 (60.71) |
| Pulmonary lesions’ progression | 4 (14.29) |
| Musculoskeletal lesions’ progression | 12 (42.86) |
| New lesions | 1 (3.57) |
| Deterioration of general condition | 11 (39.29) |
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; N, number; sd, standard deviation.